basal insulin

06/01/2002 - "Its activity profile, which lacks a pronounced peak, more closely resembles that of endogenous basal insulin than that of other intermediate- or long-acting insulins and appears more likely to be associated with a reduced incidence of hypoglycemia, particularly nocturnal hypoglycemia. "
11/01/2014 - "This article also discusses all the trials and meta-analysis done on all the current basal insulin available along with their head-to-head comparison with particular attention to glycemic control and hypoglycemic events including severe and nocturnal hypoglycemia. "
06/01/2010 - "The purpose of this study was to develop an advanced algorithm that detects pending hypoglycemia and then suspends basal insulin delivery. "
10/01/2006 - "The Diabetes Research in Children Network (DirecNet) Study Group conducted a study to determine whether stopping basal insulin could reduce the frequency of hypoglycemia occurring during exercise. "
07/01/2015 - "In naïve T2D patients initiating basal insulin, hypoglycemia prevents the increase in vasculoprotective PCs. "

01/01/2014 - "To examine changes in glycemic control for patients with type 2 diabetes mellitus (T2DM) after initiation of basal insulin and factors associated with improved glycemic control. "
12/17/2012 - "Hypoglycemic risk and improved glycemic control have to be weightened when a decision on intensification of treatment of type 2 diabetes mellitus with basal insulin is made. "
03/01/2015 - "A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data."
11/01/2015 - "Intensification of Basal Insulin Treatment Among Patients With Diabetes Mellitus Type 2 In The Netherlands."
08/01/2015 - "A variety of basal insulin preparations are used to treat patients with type 2 diabetes mellitus (T2DM). "

01/01/2013 - "Addition of IAsp with a basal insulin in patients with poor glycaemic control leads to an improvement in glycaemic profile with no major hypoglycaemia or clinically significant weight gain along with an improvement in the quality of life in patients with type 2 diabetes."
12/01/2012 - "On the basis of this study, concerns about hypoglycaemia or weight gain should not preclude initiation of basal insulin analogues in patients with poor glycaemic control on OHAs."
07/01/2015 - "The limitations of current basal insulin preparations include concerns related to their pharmacokinetic and pharmacodynamic properties, hypoglycaemia, weight gain, and perception of management complexity, including rigid dosing schedules. "
01/01/2015 - "These findings suggest that, with their complementary mechanisms of action, empagliflozin added on to basal insulin may be a useful treatment option in patients on basal insulin who need additional glycemic control without weight gain. "
09/01/2011 - "Weight gain was lowest when basal insulin was added to MET. "

01/01/2013 - "Few studies have evaluated the efficacy of using body weight to calculate the basal insulin dose. "
12/01/2015 - "Basal insulin requirement however, was different between the two groups (0.56 IU/kg of body weight in NDM vs. 0.43 IU/kg in T1DM) (P = 0.036). "
09/01/2014 - "On average, GB reduced mean BMI by 11% and mean HbA1c by 0.9% (from 8.0 to 7.1%), with a parallel 38% decrease in basal insulin requirements (expressed per kilogram of body weight). "
06/06/2012 - "  In the type 1 diabetes patients who are aged 14 or above, an association between daily basal insulin doses/body weight and fat energy ratio of meal was suggested. "
06/06/2012 - "In the multiple regression analysis among all subjects, when daily basal insulin doses/body weight was used as a dependent variable, fat energy ratio of the meal was obtained as an entered variable (P = 0.001). "

09/01/2012 - "Suspension-induced hyperglycemia is not assessed, because this study forced excessive basal insulin infusion rates. "
12/01/2015 - "When confronted with an uncontrolled A1c after reasonable titration of basal insulin, clinicians should be aware of probable postprandial contributions to hyperglycemia and consider prandial therapy. "
03/01/2015 - "Patterns of postprandial hyperglycemia after basal insulin therapy: individual and regional differences."
11/27/2013 - "After improving hyperglycemia, we challenged with oral hypoglycemic agent (OHA), and according to the responsiveness to OHA, patients were classified into three therapy groups: OHA alone (n = 103), basal insulin plus OHA (basal insulin-supported oral therapy [BOT]; n = 56) and MDI (n = 132). "
06/01/2013 - "Patients whose A1C levels remain above goal despite adequate basal insulin replacement need to evaluate and correct post-prandial hyperglycemia. "